Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

ClinicalTrials.gov ID: NCT02040766

Public ClinicalTrials.gov record NCT02040766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo. Patients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.

Study identification

NCT ID
NCT02040766
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
628 participants

Conditions and interventions

Eligibility (public fields only)

Age range
4 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2013
Primary completion
Jan 31, 2016
Completion
Feb 29, 2016
Last update posted
Nov 8, 2021

2013 – 2016

United States locations

U.S. sites
75
U.S. states
27
U.S. cities
65
Facility City State ZIP Site status
Teva Investigational Site 12346 Hoover Alabama
Teva Investigational Site 12294 Montgomery Alabama
Teva Investigational Site 10925 Phoenix Arizona
Teva Investigational Site 12349 Little Rock Arkansas
Teva Investigational Site 10903 Costa Mesa California
Teva Investigational Site 10911 Downey California
Teva Investigational Site 10901 Huntington Beach California
Teva Investigational Site 12297 Huntington Beach California
Teva Investigational Site 10880 Mission Viejo California
Teva Investigational Site 10895 Orange California
Teva Investigational Site 10924 Paramount California
Teva Investigational Site 10910 Rolling Hills Estates California
Teva Investigational Site 12343 Roseville California
Teva Investigational Site 12298 San Diego California
Teva Investigational Site 12300 San Diego California
Teva Investigational Site 12295 San Jose California
Teva Investigational Site 12312 West Covina California
Teva Investigational Site 10937 Centennial Colorado
Teva Investigational Site 10899 Colorado Springs Colorado
Teva Investigational Site 10894 Aventura Florida
Teva Investigational Site 12335 Gainesville Florida
Teva Investigational Site 12336 Homestead Florida
Teva Investigational Site 12345 Homestead Florida
Teva Investigational Site 12315 Miami Florida
Teva Investigational Site 12341 Miami Florida
Teva Investigational Site 12342 Miami Florida
Teva Investigational Site 10919 Orlando Florida
Teva Investigational Site 12281 Sarasota Florida
Teva Investigational Site 12332 Winter Park Florida
Teva Investigational Site 10935 Gainesville Georgia
Teva Investigational Site 10912 Lawrenceville Georgia
Teva Investigational Site 10927 Savannah Georgia
Teva Investigational Site 10885 Owensboro Kentucky
Teva Investigational Site 12317 Covington Louisiana
Teva Investigational Site 12296 Baltimore Maryland
Teva Investigational Site 12323 White Marsh Maryland
Teva Investigational Site 10897 North Dartmouth Massachusetts
Teva Investigational Site 10932 Ypsilanti Michigan
Teva Investigational Site 10914 Plymouth Minnesota
Teva Investigational Site 10917 Columbia Missouri
Teva Investigational Site 10916 Rolla Missouri
Teva Investigational Site 12331 Missoula Montana
Teva Investigational Site 10922 Brick New Jersey
Teva Investigational Site 10909 Ocean City New Jersey
Teva Investigational Site 12289 Verona New Jersey
Teva Investigational Site 10939 Asheville North Carolina
Teva Investigational Site 12348 Charlotte North Carolina
Teva Investigational Site 10893 Raleigh North Carolina
Teva Investigational Site 10888 Canton Ohio
Teva Investigational Site 12302 Fairfield Ohio
Teva Investigational Site 10921 Toledo Ohio
Teva Investigational Site 12285 Toledo Ohio
Teva Investigational Site 10906 Oklahoma City Oklahoma
Teva Investigational Site 10915 Oklahoma City Oklahoma
Teva Investigational Site 12314 Oklahoma City Oklahoma
Teva Investigational Site 10891 Tulsa Oklahoma
Teva Investigational Site 10892 Medford Oregon
Teva Investigational Site 10898 Portland Oregon
Teva Investigational Site 12273 Pittsburgh Pennsylvania
Teva Investigational Site 12282 Warwick Rhode Island
Teva Investigational Site 10902 North Charleston South Carolina
Teva Investigational Site 10938 Orangeburg South Carolina
Teva Investigational Site 12347 Beaumont Texas
Teva Investigational Site 10926 Boerne Texas
Teva Investigational Site 10908 Dallas Texas
Teva Investigational Site 10918 Dallas Texas
Teva Investigational Site 12291 El Paso Texas
Teva Investigational Site 12329 Live Oak Texas
Teva Investigational Site 10890 New Braunfels Texas
Teva Investigational Site 10904 San Antonio Texas
Teva Investigational Site 10929 San Antonio Texas
Teva Investigational Site 10879 Waco Texas
Teva Investigational Site 10883 Richmond Virginia
Teva Investigational Site 10886 Bellingham Washington
Teva Investigational Site 10913 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

Recently updated Asthma trials

Other public records listing Asthma. Sorted by last update posted; newest first. Not a recommendation.

All Asthma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02040766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02040766 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →